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Pharmacists were instructed to ask each person dropping off or picking up a prescrip-
tion about concurrent NHP-drug use, and the occurrence of any potential AE. Tele-
phone interviews conducted by a study team member were used to follow up if an AE 
was reported. Up to three months of active surveillance was planned in ten community 
pharmacies in Ontario. All cases were independently adjudicated for causality, serious-
ness and outcome by 2 study team members with expertise in NHPs. Algorithms used 
for adjudication included the WHO guidelines, Naranjo causality scale, and Horn 
algorithm (drug interaction probability scale). RESULTS: Over 2000 patients have 
been screened. A total of 759 reported taking NHPs and drugs concurrently, 35 were 
identiﬁed as having suspected AEs, and 15 consented to, and were available for, an 
in-depth interview. Two not previously described probable NHP-drug interactions 
have been identiﬁed including analysis of their purported CYP450 pharmacokinetic 
mechanisms. In case 1, strong sedation occurred after concomitant intake of citalo-
pram, nortriptyline, oxycodone, and melatonin. Melatonin was shown to inhibit 
CYP2C19 and thus citalopram metabolism. In case 2, heart palpitations occurred after 
concomitant intake of two NHPs containing a variety of active substances and pro-
gesterone cream use. Laboratory analyses to investigate possible mechanisms to 
explain the clinical symptoms described is ongoing. CONCLUSIONS: In this study, 
the rate of AEs suspected to be related to NHP use was 5.7%. Active surveillance of 
NHP-drug interactions and NHP-related AEs in community pharmacies is feasible and 
provides an effective way to discover unknown pharmacokinetic and pharmacody-
namic NHP-related interactions.
CANCER – Clinical Outcomes Studies
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OBJECTIVES: Along with neutropenia and anemia, thrombocytopenia is one of the 
most common hematological complications of cancer treatment. Prolonged/severe 
thrombocytopenia increases the risk of bleeding. The goal of this study was to evalu-
ate the epidemiology of thrombocytopenia among cancer patients on chemotherapy. 
METHODS: Data were collected between 2000–2007 from a large electronic 
medical records database in 18 outpatient oncology clinics throughout the US. Adult 
patients with NSCLC, breast, ovarian, H&N, and colorectal cancers were of inter-
est. Chemotherapy regimens were grouped into platinum-, anthracycline-, gem-
citabine-, and taxane- based. Thrombocytopenia (150,000 Ml) prevalence was 
examined by tumor and regimen type. RESULTS: A total of 47,159 patients [mean 
age 61, male 42%] and 75,243 chemotherapy regimens were analyzed. Breast cancer 
patients constituted 19.5%, followed by NSCLC (14.9%), colorectal (11.9%), 
ovarian (3.1%), and H&N (2.5%). Platinum-based regimens accounted for 27.8% 
of all regimens. Prevalence of post-chemo thrombocytopenia was highest among 
gemcitabine treated patients (64.2%), followed by platinum (55.5%), and lowest 
with taxane-based regimens (21.9%). Most of the patients across all treatment 
regimen groups presented with thrombocytopenia (grade 1). Eleven percent of 
patients on platinum and gemcitabine regimens, 2% in taxane-treated patients, and 
5% in anthracycline-treated patients had PC  50 r 109/L (grade 3–4). Patients with 
NSCLC and ovarian cancer had the highest incidence of thrombocytopenia. A sub-
stantial proportion of patients, 30% developed both anemia and thrombocytopenia 
after chemotherapy start. More than 90% of patients with thrombocytopenia grade 
1–3 also had anemia grade 1 or 2. Twenty percent of those with grade 4 thrombocy-
topenia presented with anemia grade 3–4. Of these, 16.7% had NSCLC, 16.2% 
were breast cancer patients, and 9.1% were colorectal cancer patients. Platelet trans-
fusions were rare (5% of all chemotherapy-treated patients). CONCLUSIONS: 
Thrombocytopenia was common in this large cohort of cancer patients on 
 chemotherapy. A substantial proportion of patients developed both anemia and 
thrombocytopenia.
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OBJECTIVES: Cancer patients receiving chemotherapy may often require chemo-
therapy dose delays and dose reductions due to chemotherapy-induced side effects 
such as thrombocytopenia, neutropenia, and anemia. In responsive cancers, such dose 
delay and dose reduction of chemotherapy may be associated with decreased effective-
ness and poorer clinical outcomes. In this study, we analyzed the characteristics of 
dose delay among cancer patients on chemotherapy. METHODS: Data from 2000–
2007 from a large electronic database of outpatient oncology clinics in the US were 
analyzed. Adult patients with a cancer diagnosis and complete chemotherapy plan 
information were eligible for this analysis. Chemotherapies were grouped into plati-
num-, anthracycline-, gemcitabine-, taxane-based, and other. The planned cycle dura-
tion was compared to the actual duration. A difference of more than 7 days was 
deﬁned as a cycle delay. RESULTS: The dataset included 47,159 cancer patients (mean 
age 61 (SD 13), male 42%) and 75,243 chemotherapy regimens. A total of 26,317 
patients (113,175 chemo cycles) had complete chemotherapy plan information. Of 
these, 5961 (22.7%) experienced chemo delays in 9293 cycles (8%) during chemo-
therapy. The average length of delay was 17 days (SD, 8 days; median, 14 days); 25% 
of the delays were more than 3 weeks. Tumor types of the 5,961 patients with cycle 
delays included, colorectal cancer (20.3%), NSCLC (18.6%), breast cancer (15.2%), 
ovarian (4.4%), and H&N (2.9%). The reasons for delaying chemo were not speciﬁed 
in the database. However, many (60%) experienced anemia (Hb  11 g/dL) or throm-
bocytopenia (150,000 Ml, 62%) at some point during chemotherapy. CONCLU-
SIONS: Chemotherapy cycle delays were relatively common in this large group of 
cancer patients. While decisions to delay therapy were multi-factorial, further research 
is needed to investigate the reasons, preventable measures, clinical and cost outcomes 
of these delays.
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OBJECTIVES: As comorbidity has a direct impact on choice of cancer treatment and 
patient prognosis after diagnosis, this study compared the prevalence and incidence 
of comorbidity among head and neck cancer (HNC) patients to a cancer-free popula-
tion in the Netherlands. METHODS: Patients diagnosed with oral cavity, pharynx 
(excluding nasopharynx), and larynx cancer between 2000–2006 were selected from 
the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient was matched 
by age and gender to four cancer-free controls selected from the PHARMO RLS with 
date of cancer diagnosis selected as the index date for both cohorts. Comorbidities 
including diabetes, cardiovascular disease (CVD), anaemia, asthma/COPD, pneumo-
nia, and depression were identiﬁed by prescription and/or hospitalisation data. Preva-
lence ratios and hazard ratios (HRs) were used to compare the occurence of events 
before and after diagnosis, respectively. RESULTS: Patients diagnosed with oral 
cavity, pharynx (excluding nasopharynx), and larynx cancer between 2000–2006 were 
selected from the PHARMO RLS and Eindhoven Cancer Registry. Each HNC patient 
was matched by age and gender to four cancer-free controls selected from the 
PHARMO RLS with date of cancer diagnosis selected as the index date for both 
cohorts. Comorbidities including diabetes, cardiovascular disease (CVD), anaemia, 
asthma/COPD, pneumonia, and depression were identiﬁed by prescription and/or 
hospitalisation data. Prevalence ratios and hazard ratios (HRs) were used to compare 
the occurence of events before and after diagnosis, respectively. CONCLUSIONS: 
HNC patients suffer from signiﬁcantly higher prevalence and incidence of both chronic 
and acute comorbidies, compared to cancer-free controls. These conditions may affect 
patient eligibity for aggressive treatment and place them at higher mortality risk.
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OBJECTIVES: Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a com-
plication of long-term bisphosphonate (BP) use. Given the beneﬁcial effects of BP on 
bone quality in patients with cancer or osteoporosis, it is of great importance to review 
the risk as it relates to time-to-event or the cumulative dose until the onset of the 
disease. METHODS: Here, we report on a review of 71 case series published since 
2003. We calculated the weighted means of time to event, as well as the minimum 
reported time and dose for zoledronate, pamidronate, and oral bisphosphonates. 
RESULTS: The mean time to BONJ after zoledronate treatment was calculated at 1.8 
years and the minimum was 10 months; after pamidronate the mean time was 2.8 
years and the minimum was 18 months; and after oral BP therapy the mean time was 
4.6 years and the minimum was 3 years. CONCLUSIONS: Zoledronic acid seems to 
be the most potent among the N-containing BPs. Factors that seem to affect BONJ 
and time to event were invasive dental procedures, and other comorbid factors such 
as increased age, rheumatoid arthritis, diabetes, use of corticosteroids, Vitamin D 
deﬁciency, and more. Understanding the pathophysiology of the disease requires 
further research.
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OBJECTIVES: To study occurrence of thromboembolic (TE) events before and after 
RCC diagnosis compared to cancer-free controls as this information is lacking in 
published literature. METHODS: RCC patients were selected from PALGA, a Dutch 
pathology database, and linked to the PHARMO record linkage system (PHARMO 
RLS) which includes drug use and hospitalization data in the Netherlands. RCC 
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patients from 2000 to 2007 were matched 1:10 by age and gender to cancer-free 
controls selected from the PHARMO RLS with date of diagnosis as the index date 
for both RCC patients and their controls. TE events were deﬁned as any venous TE 
event or arterial TE event requiring hospitalization in the 12 months before or after 
index date. RESULTS: A total of 973 RCC patients were included, 6% of whom 
underwent nephrectomy. The proportion of patients with any TE event was similar 
before (2.0%, 95% CI: 1.2–3.0%) and after (1.4%, 95% CI: 0.8–2.4%) RCC diag-
nosis. Arterial TE events were more common prior to diagnosis (1.6%, 95% CI: 0.9–
2.7%) than post-diagnosis (0.5%, 95% CI: 0.2–1.2%), whereas venous TE events 
were less common prior to diagnosis (0.3%, 95% CI: 0.1–0.9%) than post-diagnosis 
(0.9%, 95% CI: 0.4–1.8%). Compared to cancer-free controls, RCC patients were 
more likely to have had a pre-diagnosis (odds ratio  2.7, 95% CI: 1.6–4.4) or post-
diagnosis (hazard ratio  2.1, 95% CI: 1.2–3.7) TE event. CONCLUSIONS: In this 
population-based study, RCC patients were twice as likely to develop TE events 
compared to cancer-free controls, although frequency of events was low. These results 
emphasize the need for careful observation of RCC patients after diagnosis.
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OBJECTIVES: TO compare efﬁcacy and safety of lenograstim and ﬁlgrastim in stem 
cell mobilization in healthy donors (allogenic transplantation) and in oncological 
patients (autologous transplantation). METHODS: Comparison was based on ran-
domized controlled trials (RCTs) identiﬁed by means of systematic review, carried out 
according to the Cochrane Collaboration guidelines. The most important medical 
databases were searched (EMBASE, MEDLINE, CENTRAL). Two reviewers indepen-
dently selected trials, assessed their quality and extracted data. Meta-analysis of 
head-to-head trials was performed to compare lenograstim and ﬁlgrastim in stem cell 
mobilization in healthy donors and oncological patients. RESULTS: The results of 4 
RCTs in healthy donors and 3 RCTs in oncological patients were included in the 
analysis. For healthy donors mobilization with lenograstim resulted in higher number 
of CD34 cells harvested than mobilization with ﬁlgrastim (WMD  0.66 r 106 per 
kg of body weight [0.05; 1.26]). No differences between lenograstim and ﬁlgrastim 
were found in the number of donors requiring second apheresis (RR  0.91 [0.62; 
1.35]). Adverse events rates were similar in both arms. Most common adverse events 
including bone pain and arthralgia. For oncological patients no differences in the 
number of patients that gained target CD34 cells (2 r 106) were found (RR  0.72 
[0.33; 1.55]). Results for hematological recovery are inconsistent. No signiﬁcant 
differences in the incidence of neutropenia were noted (RR  0.72 [0.50; 1.03]) 
whereas platelet transfusions were more frequent in ﬁlgrastim treated patients than in 
lenograstim group (RR  0.16 [0.04; 0.67]). The length of hospital stay after trans-
plantation was similar in both groups. No signiﬁcant differences regarding safety 
outcomes were reported. CONCLUSIONS: In healthy donors lenograstim is more 
potent than ﬁlgrastim in stem cell mobilization into peripheral blood and no differ-
ences in safety proﬁles between two drugs were noted. In oncological patients both 
drugs has similar impact on stem cell mobilization while lenograstim dicreases the 
risk of platelet transfusion. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: This study compared efﬁcacy and safety of allogenic peripheral blood 
stem cell transplantation (PBSCT) after mobilization with either lenograstim or ﬁl-
grastim. METHODS: Comparison was based on randomized controlled trials (RCT) 
identiﬁed by means of systematic review, carried out according to the Cochrane Col-
laboration guidelines. The most important medical databases were searched (EMBASE, 
MEDLINE, CENTRAL). Two reviewers independently selected trials, assessed their 
quality and extracted data. Since head-to-head trials were not found, indirect com-
parison using Bucher’s method was performed. RESULTS: The results of 2 RCTs for 
PBSCT after lenograstim mobilization and 7 for PBSCT with ﬁlgrastim were included. 
In all trials PBSCT was compared with bone marrow transplantation (BMT). No sig-
niﬁcant differences between lenograstim and ﬁlgrastim were found in mortality rate 
(RR  0.84 [0.49; 1.42]) and relapse rate (RR  0.69 [0.19; 2.49]). PBSCT after 
mobilization with lenograstim comparing to BMT does not increase the risk of acute 
graft versus host disease (GvHD) (RR  1.06 [0.73; 1.53]) whereas PBSCT after ﬁl-
grastim use is associated with higher risk of acute GvHD than BMT (RR  1.19 [1.03; 
1.37]). However indirect comparison results in similar incidence of acute GvHD 
(RR  0.89 [0.60; 1.32]. The was also no difference between lenograstim and ﬁlgrastim 
in respect to chronic GvHD (RR  1.33 [0.84; 2.11]. Lenograstim and ﬁlgrastim 
in PBSCT resulted in similar mortality rate due to GvHD (RR  0.55 [0.19; 1.59]), 
treatement realted mortality (RR  1.11 [0.60; 2.04]). No differences in hospital 
admissions for donors mobilized with lenograstim and ﬁlgrastim were identiﬁed 
(RR  1.04 [0.60; 1.79]). CONCLUSIONS: Indirect comparisons indicate similar 
efﬁcacy and safety of PBSCT after mobilization with lenograstim and PBSCT after 
mobilization with ﬁlgrastim. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: To describe the prevalence of comorbidities in the newly diagnosed 
mCRC population. METHODS: The study used a large US claims database. Patients 
aged q18 with newly diagnosed mCRC between January 2005 and June 2008 were 
selected using the ICD-9 diagnosis codes (CRC: 153.x [excluding 153.5], 154.0, 154.1, 
154.8; distant metastasis: 196.0, 196.1, 196.3, 196.5, 197.x (excluding 197.5), 198, 
199.0). The initial mCRC diagnosis date was deﬁned as the index date. One-year 
continuous medical and drug beneﬁt coverage prior to the index date was required. 
Medical diagnoses and medication treatments were examined. All comorbidities were 
estimated during 1-year except for traumatic conditions which were assessed for 30-
day prior to the index date. RESULTS: Based on the selection criteria, 12,648 patients 
were included with mean (ostandard deviation) age of 66.3 (o13.0) years, 54% male, 
and 70% with colon primary. Distribution of metastases included liver (40%), lung 
(14%), bone (6%), and brain (3%). The most prevalent comorbidity was cardiovas-
cular disease (CVD) (62% of patients) including hypertension (41%), coronary artery 
disease (17%), congestive heart failure (7%), dysrhythmias (14%), arterial thrombo-
embolism including ischemic heart disease (18.6%), and venous thromboembolism 
(6%). Over 10% of patients had a major surgery, bone fracture, or open wound 30 
days prior to mCRC diagnosis; 31% had a history of bleeding; and nearly 12% of 
patients were treated with anticoagulant and 6% with antiplatelet agents. Addition-
ally, 19% of patients had diabetes, 8% had renal failure or insufﬁciency, and 5% had 
skin disorders. Patients q65 years old had a signiﬁcantly higher CVD prevalence (73%; 
p  0.001). CONCLUSIONS: Comorbid medical conditions are common in patients 
with mCRC. CVD is the most prevalent comorbidity and affects approximately ¾ of 
patients over age 65. It is important to assess comorbidities in all patients with mCRC 
since their presence may impact treatment decision making.
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OBJECTIVES: Current options for colorectal cancer (CRC) screening include imaging 
procedures such as colonoscopy and ﬂexible sigmoidoscopy, guaiac fecal occult blood 
tests (gFOBT), and fecal immunochemical tests (FIT). Compliance with screening for 
CRC guidelines remains low among average-risk adults, at least partly because of low 
patient acceptance of available tests due to their invasiveness, inconvenience, and 
perceived safety risks. Serum tests are noninvasive, convenient, and safe, and may 
improve compliance. We systematically reviewed the literature to assess the current 
status of serum tests and other screening tests for CRC. METHODS: We analyzed 
studies of CRC screening tests identiﬁed in a search of English-language MEDLINE-
indexed articles published in the 3 years prior to March 2009 and non-MEDLINE-
indexed sources such as organization websites, meeting abstracts, and government 
publications. RESULTS: We identiﬁed 123 primary studies from MEDLINE and 45 
from non-MEDLINE sources for a total of 168 pertaining to tests or biomarkers for 
early diagnosis of CRC. Serum biomarkers being evaluated include tumor associated 
antigens, cytokines, anti-apoptotic and pro-growth factors, and hypermethylated 
DNA. Biomarkers under development have signiﬁcantly higher sensitivity for CRC 
than for adenomatous polyps, making them more effective for cancer detection than 
prevention. CRC sensitivity and speciﬁcity of certain serum biomarkers and serum 
biomarker panels under development are better than those of the existing test gFOBT 
and equivalent or better than those of FIT. However, most biomarkers in development 
are common to other cancers and diseases, reducing their speciﬁcity for CRC. CON-
CLUSIONS: Several serum biomarkers show promise in detecting CRC, but require 
testing in large, average-risk populations. Unless biomarkers are identiﬁed that are 
more speciﬁc for adenomas and/or CRC than currently known, and because of the 
heterogeneity of CRC, the approach most likely to be successful would involve the 
combination of multiple serum biomarkers to create a distinctive CRC biomarker 
proﬁle.
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OBJECTIVES: GISTs are rare tumors of the GI tract. In France, their incidence is 
estimated to be 9–12/106 inhabitants/year. Imatinib has been approved to treat 
unresectable and/or metastatic Kit-positive GISTs since 2002, but information on 
routine use, safety and efﬁcacy in unselected “real life” setting is lacking. An obser-
vational cohort (EPIGIST) in France was designed to provide data on survival, safety 
and treatment patterns and quality of life. METHODS: EPIGIST is a nationwide 
